WAYNE, Pa. — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive...

SAN CARLOS, Calif. — Cerepeut, Inc., a biotechnology company developing mitochondrial therapeutics for neurodegenerative disease, today announced publication of a landmark study in Neuron revealing why the brain turns on itself in Alzheimer’s disease and related disorders, and unveiling a drug candidate designed to stop it. Tau is a well-known driver...

PALO ALTO, Calif. — Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, today announced that it has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH). The award funds a research...